What We Do
Three pillars. One purpose. Formulations, Biopharmaceuticals and Medical Devices — united to elevate life through science and care.
Building Novel Solutions for Malaria Elimination by 2030
Augmenting Opunika® extracts through Nano-technology to help eliminate malaria by 2030.
Malaria is one of the major public health problems of the country. Around 1,50,000 laboratory confirmed cases of malaria are annually reported in India. Around 50% of the total malaria cases reported is due to P. falciparum. Malaria-associated maternal illness and anaemia, preterm birth and low birthweight new-borns are mostly the result of P. falciparum. Maternal anaemia, of which malaria remains an important contributor, puts the mother at increased risk of death before and after childbirth. This also leads to preterm births and children of low weight at birth, causing problems with child growth and cognitive development, as well as being major risk factors for perinatal, neonatal and infant mortality. Newer studies and reports are also suggesting towards increased resistance of Plasmodium spp. to the latest line of treatment (Artemisinin).
Since 2000, there has been a significant increase in the number of countries that have moved towards malaria elimination. Of the 106 countries with ongoing malaria transmission in 2000, 15 countries achieved malaria elimination, 57 achieved reductions of least 75% and 18 countries reduced their malaria cases by 50−75%. With such encouraging case studies worldwide, India too has formulated a National Framework for Malaria Elimination in India (2016-2030).
A critical gap is the absence and unavailability of a suitable chemo-prophylactic drug or formulation in India or globally that can help to bring down the transmission rates thereby helping to make the transition from high API to lower degrees. The prophylactic formulations currently available for malaria suffer from major handicaps like being contraindicated for pregnant and feeding women, children and people with certain genetic conditions. These medications also do not act for enough time frame to encourage wide adoption by population at risk. Malaria eradication necessitates new tools to fight the evolving and complex Plasmodium pathogens. Eliminating parasites in the human liver (host) prevents disease progression in the individual and eliminates transmission, as parasites never reach the blood stage. Despite imperfections in the evaluation model at the liver stages, hepatic targeted prophylactic drugs can play the game changer.
Having realized this felt need, Consytel® Life Sciences has decided to venture into a program to develop a prophylactic antimalarial formulation to address the critical gap.
Our Offerings
We deliver innovation across three verticals — Formulations, Biopharmaceuticals, and Medical Devices — to advance health and well-being.
Routine and stat testing, special biochemical tests, metabolic tests, drug-level monitoring.
Routine and stat testing, special biochemical tests, metabolic tests, drug-level monitoring.
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test.
Accurate Product Testing by Expert Scientists
LIST OF ALLFrequently Asked Questions
What products are cosmetics?
Podcasting operational change management inside of workflows to establish a framework. Taking seamless key performance indicators offline to maximise the long tail. Keeping your eye on the ball while performing a deep dive on the start-up mentality to derive convergence on cross-platform integration.
Collaboratively administrate empowered markets via plug-and-play networks. Dynamically procrastinate B2C users after installed base benefits. Dramatically visualize customer directed convergence without revolutionary ROI.
Is animal testing legally required?
Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward, a new normal that has evolved from generation X is on the runway heading towards a streamlined cloud solution. User generated content in real-time will have multiple touchpoints for offshoring.
What are the alternatives to testing?
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Organically grow the holistic world view of disruptive innovation via workplace diversity and empowerment.
Where is animal testing safe?
Collaboratively administrate empowered markets via plug-and-play networks. Dynamically procrastinate B2C users after installed base benefits. Dramatically visualize customer directed convergence without revolutionary ROI.
Our Enabling Partners
Subscribe Our Newsletter
Subscribe Our Newsletter
Consytel® Life Sciences Pvt Ltd. is a pioneering biotech startup in India, developing botanical drugs, smart medical devices and innovative Biopharmaceutical solutions.
Quick Links
Offerings
© 2025 Consytel®. All rights reserved